New Jebsen Centre for MED at Klinmed
Researchers at the new K G Jebsen Centre for B Cell Malignancies will study malignant B-cells which are often found in leukaemia, lymphoma and bone marrow cancer.
From the left: Hans-Jørgen Lund (Klinmed), Anne Maria Haga (Stiftelsen K G Jebsen), Professor Ludvig Andre Munthe (Klinmed), Oddveig Åsheim (Stiftelsen K G Jebsen) and several others met up at the end of January at the Faculty’s premises in Sogn Arena to prepare for the start-up of the new centre. Photo: Øystein Horgmo, UiO
They have high ambitions for research at the K. G .Jebsen Centre for B Cell Malignancies now that several expert academic groups are forming a new centre. Professor Ludvig A. Munthe at the Institute for Clinical Medicine is to head the new centre. He says: “We are pleased to bring several research groups together to create a K G Jebsen Centre with researchers from both the Faculty of Medicine and Oslo University Hospital.”
The Faculty’s management wishes to heartily congratulate Director Ludvig Munthe and the other researchers at the centre. The Faculty of Medicine is very grateful for the funding that will give the researchers a new opportunity to develop their own research within their specialist fields.
“Becoming a Jebsen Centre will provide the researchers with status and a brand that will mean a lot, both for their faith in their own research and for their work in developing a world-leading community in this important field of research”, says Pro-Dean of Research and Innovation Hilde Nebb.
She continues: “It is fantastic that these researchers have received this prestigious funding and that Ludvig Munthe, who is a young researcher with his career ahead of him, has been given the opportunity to head such a centre.”
Becoming a Jebsen Centre provides a massive research boost
Each new centre is selected as the result of tough competition and receives NOK 18 million from the "Stiftelsen Kristian Gerhard Jebsen" foundation. The foundation wants to boost research and to contribute towards patients benefitting more rapidly from the results. The new centre also receives considerable funding from the faculty and the university.
“This will enable us to highlight diseases like leukemia, lymphoma and bone marrow cancer, both by focussing collectively on the research, but also in order to represent our patients. For many years each group has been at the forefront of research in the field, independently distinguishing themselves. Now our activities are being gathered and we can make a concerted effort together,” says Professor Munthe.
“We have also been a major player and trendsetter in trialling new treatment methods,” explains the new centre head. “We can now employ clinical Phd students, post-doctoral researchers and nurses and improve our opportunities for becoming involved in new treatments for this group of patients. This is sorely needed, since many of these types of cancer are still incurable.”
Basal medicine and innovation
The new Jebsen Centre will identify causal and key factors which cause cancer cell growth, characterise variations between patient groups and undertake large-scale drug-testing in order to create personalised medicines. The Centre’s researchers will also develop new biological treatment principles and facilitate new forms of cell therapy.
Professor Munthe goes on to say: “Our clinical research will be firmly rooted in in-depth basal research and innovative work. We will not only explain the causal connections, but also invent new drugs.”
Valuable cooperation with Oslo University Hospital.
“I am looking forward to following the continuation of this research which is so important for personalised cancer treatment and which employs new research methods in order to solve both basal and clinical issues and which provide great opportunities for new innovations. This research would not have been possible without proximity to the patients. This is made possible by the close integration and cooperation that exists between the Faculty of Medicine and Oslo University Hospital,” says Pro-Dean of Research and Innovation Hilde Nebb.
Successful UiB research on genome-directed cancer therapy
This year’s second centre was given to The University of Bergen. At the K. G. Jebsen Centre for Genome-Directed Therapy in Cancer, researchers will exploit genetic defects of cancer cells in order to improve the methods used to identify patients who would benefit from specific types of treatment. In the long term they will use this research to develop more effective therapies which could help heal many patients who cannot currently be cured.
The centre in Bergen will concentrate in particular on breast cancer, colon cancer, sarcomas, lung cancer, bladder cancer and prostate cancer.
Facts about the Stiftelsen Kristian Gerhard Jebsen foundation
The foundation was set up to commemorate shipowner Kristian Gerhard Jebsen and his contribution to Norwegian and international shipping and industry. The foundation was established by Aud Jebsen and her family in 2009. The foundation is intended to operate for up to 30 years, and it will be able to provide considerable financial support for various socially beneficial purposes.
The "Stiftelsen Kristian Gerhard Jebsen" foundation has relatively comprehensive statutory objectives. Up until recently the foundation has been involved in cultural affairs, medical research and marine/maritime research and activities. The foundation is keen for its activities to strengthen free, independent Norwegian research and develop strong international research communities in Norway.
The centre website: K G Jebsen Centre for B cell malignancies
The new centre in Bergen: New K.G. Jebsen Centre for Genome-Directed Therapy in Cancer